Vivian Liu to Resign from the Board of Directors of Cesca Therapeutics Inc., Effective Upon the Expiration of Director Term on June 22, 2018
June 13, 2018 at 04:59 pm
Share
On June 12, 2018, Vivian Liu, the Chief Operating Officer, Corporate Secretary and a director of Cesca Therapeutics Inc. notified the Company that she has decided to resign from the company’s Board of Directors effective upon the expiration of her director term on June 22, 2018. As a result, Ms. Liu will not accept reelection as a director at the Company’s Annual Meeting of Stockholders to be held on June 22, 2018. Ms. Liu will continue to serve as the Chief Operating Officer and Corporate Secretary for the Company and as a director and executive officer of the Company’s majority-owned ThermoGenesis Corp. subsidiary. As a result of Ms. Liu’s resignation as director, it is anticipated that the Company’s Board of Directors will vote on June 22, 2018 to decrease the size of the Board of Directors from 6 members to 5 members.
ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. The Company provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services. Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System. Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The Company markets and sells its medical device products through independent distributors.